Opto Circuits is currently trading at Rs. 22.15, up by 0.55 points or 2.55% from its previous closing of Rs. 21.60 on the BSE.
The scrip opened at Rs. 21.95 and has touched a high and low of Rs. 22.65 and Rs. 21.10 respectively. So far 6,15,000 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 165.55 on 06-Jul-2012 and a 52 week low of Rs. 20.10 on 11-Jun-2013.
Last one week high and low of the scrip stood at Rs. 25.60 and Rs. 20.10 respectively. The current market cap of the company is Rs. 536.00 crore.
The promoters holding in the company stood at 28.17% while Institutions and Non-Institutions held 36.98% and 34.85% respectively.
Eurocor Gmbh, a group company of Opto Circuits (India), and its partner Micell Technologies, Inc. received CE (Conformite Europeenne) Mark approval for its MiStent Sirolimus Eluting Absorbable Polymer Coronary Stent System (MiStent SES) introducing a thin-strut stent that features elimination of the coating from the stent in 45-60 days and the complete absorption of the polymer coating within 90 days.
The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events. The MiStent SES approval is supported by in-depth clinical analysis from the DESSOLVE I and DESSOLVE II clinical trials. With this CE Mark approval, Micell is preparing to make the MiStent SES commercially available in Europe and other markets where CE Mark approval can expedite the registration process.
Opto Circuits India is a multinational medical device company headquartered out of Bengaluru, India. The company designs, develop, manufacture, market and distribute a range of medical products that are used by healthcare establishments in more than 150 countries.
| Company Name | CMP |
|---|---|
| Poly Medicure | 2581.85 |
| Nureca Ltd. | 273.50 |
| Prevest Denpro | 540.00 |
| Centenial Surgical | 125.00 |
| Raaj Medisafe India | 86.01 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
